OGN vs. BBIO, PRGO, ALKS, ACAD, APLS, INSM, ITCI, IMGN, FOLD, and EVO
Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include BridgeBio Pharma (BBIO), Perrigo (PRGO), Alkermes (ALKS), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Insmed (INSM), Intra-Cellular Therapies (ITCI), ImmunoGen (IMGN), Amicus Therapeutics (FOLD), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.
Organon & Co. (NYSE:OGN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Organon & Co. has a net margin of 12.22% compared to BridgeBio Pharma's net margin of -10,096.65%. BridgeBio Pharma's return on equity of 0.00% beat Organon & Co.'s return on equity.
Organon & Co. has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Organon & Co. currently has a consensus price target of $28.25, indicating a potential upside of 73.42%. BridgeBio Pharma has a consensus price target of $37.30, indicating a potential upside of 46.68%. Given Organon & Co.'s higher probable upside, equities research analysts clearly believe Organon & Co. is more favorable than BridgeBio Pharma.
BridgeBio Pharma received 114 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 65.80% of users gave BridgeBio Pharma an outperform vote while only 32.50% of users gave Organon & Co. an outperform vote.
77.1% of Organon & Co. shares are held by institutional investors. Comparatively, 90.9% of BridgeBio Pharma shares are held by institutional investors. 1.2% of Organon & Co. shares are held by insiders. Comparatively, 28.5% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
In the previous week, BridgeBio Pharma had 1 more articles in the media than Organon & Co.. MarketBeat recorded 6 mentions for BridgeBio Pharma and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.78 beat BridgeBio Pharma's score of 0.69 indicating that Organon & Co. is being referred to more favorably in the media.
Summary
BridgeBio Pharma beats Organon & Co. on 10 of the 18 factors compared between the two stocks.
Get Organon & Co. News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organon & Co. Competitors List
Related Companies and Tools
